June 29, 2017 7:38am

 

As sector end goes up and down.

 

Where is the pivot set for buyers and sellers?

 

Pre-open indication:  five (5), 2 BUY and 3 SELLS

 

A critical indication ahead of “our” universe’s open!

 

Are you a subscriber?  If not – you’re missing the realities of “our” universe! 

 

 

 

I know what a company is supposed to look like, be like, and smell like to succeed!

 

 

Slightly higher opening expected

 

Dow futures are UP +0.10% and NASDAQ futures are DOWN -0.11%

 

U.S. stock index futures pointed to a slightly higher open on Thursday, as investors geared up for a slew of data announcements during trade, while keeping an eye on the central banking sphere.

European bourses were mixed as investors awaited a NATO meeting of defense ministers and digested major buyback plans from some of the U.S.' biggest banks.

Asian markets closed higher, taking cues from a stronger finish in U.S. markets, as traders digested comments from top central bankers overnight.

 

Data docket: real Gross Domestic Product (GDP) data is due out at 8.30 a.m. ET, along with jobless claims. Meanwhile, investors will likely be keeping a close eye on yields in the bond market, as yields move higher.

 

 

The cell therapy sector closed POSITIVE on Wednesday, NEGATIVE on Tuesday, and POSITIVE on Monday, Friday and last Thursday.

The cell therapy sector’s record over the last 5 sessions (of 43 covered companies):

·         Wednesday closed POSITIVE with 9 decliners, 31 advancers and 3 flats;

·         Tuesday closed NEGATIVE with 32 decliners, 10 advancers and 1 flat;

·         Monday closed POSITIVE with 15 decliners, 26 advancers and 2 flats;

·         Friday closed POSITIVE with 14 decliners, 24 advancers and 5 flats;

·         Last Thursday closed POSITIVE with 12 decliners, 27 advancers and 4 flats

 

 

Remembering Wednesday’s closing bell newsletter, “the updraft of the oversold returns on the back of a downslide as the sector responds to volatility.”

  • Reiterating, “Just when I thought appreciation would disappear, a whipsaw.”

Let’s see how Thursday spins … the seesaw‘s pivot is set to weigh which side?

 

… My view is toward sellers…

 

 

What did I see on Wednesday, The NASDAQ rose 1.4% to 6,234. The S&P 500 index SPX, +0.88% climbed 0.9% at 2,440, representing the benchmark's best daily rise since April 24. The Dow gained 0.7% at 21,454. Those moves come a day after equities saw their worst selloff in more than a month … the small-cap Russell 2000 RUT, +1.55% nearly closed at a record, finishing up about 1.5% on the day, and highlighting the broad-based nature of the rally.

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, 10.05 … DOWN -9.13% as Tuesday traded above 11.07 … up +11.72%

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed up +1.93% on Wednesday, the aftermarket indicated a positive +0.32% and indicated a negative -0.06% in Thursday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Wednesday up +2.55%, the aftermarket indication was a positive +0.32% and is NOT indicating In Thursday’s pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed up +0.53% Wednesday, the aftermarket indication was a positive +0.66% and is NOT indicating in Thursday’s pre-open;
  • The iShares Russell 2000 (IWM) closed up +1.53% on Wednesday, the aftermarket indication was a positive +0.30% and indicating a POSITIVE +0.15% in Thursday’s pre-open

 

 

Companies in my headlights:

………. We should be riding the seesaw of pricing …….

bluebird bio (BLUE) closed up +$2.20 to $109.10 following Tuesday’s  $106.90 (-$4.20) , Monday’s $111.10 (-$0.90) following Friday’s $112.00 (-$6.50) after Thursday’s $118.50 (-$1.80) following Wednesday’s $120.30 (+$7.30). June started at $79.20; saw a high of $120.30 and a low of $79.20. The aftermarket indication is a negative -$1.70 or -1.59% - SELL on offering, BUY on re- capitalization and SELL on offering upside;

Histogenics (HSGX) closed down -$0.01 to $1.79 after Tuesday’s $1.80 (-$0.05). HSGX’s P3 Clinical Trial of NeoCart® enrollment completed to treat knee Cartilage damage. HSGX is also on track for top-line 1 year powered data and potential BLA filing in Q3/18 with a potential BLA to the FDA shortly thereafter and, if approved, launching NeoCart in the second half of 2019. June started at $1.65; saw a high of $1.85 and a low of $1.60. Twice we have seen $1.85 and $1.68. – Maintaining BUY;

Juno Therapeutics (JUNO) closed up +$2.02 to $31.26 following Tuesday’s $29.34and Monday’s $29.70, last Friday’s $29.00 and the previous Thursday’s $26.98.  The aftermarket indication is a positive +0.10 or +0.32% and the pre-market indication is a positive +$0.11 or +0.35 – BUY;

Kite Pharma (KITE) closed up +$4.82 to $102.87. It’s getting rich after a patent grant and upside.  June started at $74.66; saw a high of $102.87 and a low of $74.66. The aftermarket indication is a positive +$0.62 or +0.60% - SELL;

Osiris (OSIR) closed up +$0.43 to $6.75 following Tuesday’s $6.32 (+$0.13), Friday’s $6.18 (+$0.29). June started at $6.05; saw a high of $6.75 and a low of $5.60 which was seen twice in the month. In five (5) sessions, there is a $0.90 or 13.3% premium in the share price. A new CEO’s announcement helps the pricing but, doesn’t lighten the load of its legal issues. Still a pink sheet listed company – Maintaining SELL; 

 

 

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.